Publications

Detailed Information

Differential Expression of Glut1 in Pulmonary Neuroendocrine Tumors: Correlation with Histological Grade

DC Field Value Language
dc.contributor.authorLee, Hyun Ju-
dc.contributor.authorYoo, Seol Bong-
dc.contributor.authorLee, Won Woo-
dc.contributor.authorChung, Doo Hyun-
dc.contributor.authorChung, Jin-Haeng-
dc.contributor.authorSeo, Jeong-Wook-
dc.date.accessioned2012-05-31T00:59:03Z-
dc.date.available2012-05-31T00:59:03Z-
dc.date.issued2009-06-
dc.identifier.citationKOREAN JOURNAL OF PATHOLOGY; Vol.43 3; 201-205ko_KR
dc.identifier.issn1738-1843-
dc.identifier.urihttps://hdl.handle.net/10371/76640-
dc.description.abstractBackground : Increased glucose uptake, a process that is mediated by glucose transporter (Glut1) proteins, is an important metabolic feature in a variety of cancer cells. The overexpression of Glut1 in human cancers is known to be related to a variety of histopathological parameters, including histological grade, proliferation rate, and lymphatic invasion. The principal objective of this study was to evaluate Glut1 expression in the spectrum of pulmonary neuroendocrine (NE) tumors including typical carcinoid tumor (TC), atypical carcinoid tumor (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell carcinoma (SCC), and to characterize the relationship between Glut1 expression and the histologic grade of NE tumors. Methods : 19 TC, 7 AC, 13 LCNEC, and 6 SCC patients were included in this study. The percentages of Glut1-positive tumor cells in these patients were determined. For statistical analysis, Glut1 expression was subdivided into a Glut1-low expression group (0-30%) and a Glut1-high expression group (31-90%). Results : In our subgroup analyses, the histological grade of pulmonary neuroendocrine (NE) tumors was significantly correlated with Glut1 expression; TC (n=19, 3.6 +/- 4.2%), AC (n=7, 20.0 +/- 4.9%), LCNEC (n=13, 60.0 +/- 21.1%), and SCC (n= 6, 74.2 +/- 16.9%). Glut1-high expression was significantly associated with high-grade NE tumors such as LCNEC and SCC (n=19, 62.6 +/- 21.0%) (p=0.000). Conclusions: The results of this study appear to indicate that Glut1 overexpression is a consistent feature of high-grade NE lung tumors.ko_KR
dc.description.sponsorshipThis work was supported by grant no 02-2008-029
from the SNUBH Research Fund and partly supported
by the Korean Science & Engineering Foundation
(KOSEF) through the Tumor Immunity Medical
Research Center at Seoul National University College
of Medicine.
ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN SOCIETY PATHOLOGISTSko_KR
dc.subjectGLUT1 Proteinko_KR
dc.subjectImmunohistochemistryko_KR
dc.subjectLung neoplasmsko_KR
dc.subjectGlucose transporterko_KR
dc.subjectNeuroendocrine tumorsko_KR
dc.titleDifferential Expression of Glut1 in Pulmonary Neuroendocrine Tumors: Correlation with Histological Gradeko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이현주-
dc.contributor.AlternativeAuthor유설봉-
dc.contributor.AlternativeAuthor이원우-
dc.contributor.AlternativeAuthor정두현-
dc.contributor.AlternativeAuthor서정욱-
dc.contributor.AlternativeAuthor정진행-
dc.identifier.doi10.4132/KoreanJPathol.2009.43.3.201-
dc.citation.journaltitleKOREAN JOURNAL OF PATHOLOGY-
dc.description.citedreferenceSong YS, 2008, LUNG CANCER, V61, P54, DOI 10.1016/j.lungcan.2007.11.012-
dc.description.citedreferenceNguyen XC, 2007, EUR J RADIOL, V62, P214, DOI 10.1016/j.ejrad.2006.12.008-
dc.description.citedreferenceKhandani AH, 2007, NUCL MED COMMUN, V28, P173-
dc.description.citedreferenceChung JH, 2004, J NUCL MED, V45, P999-
dc.description.citedreferenceTRAVIS WD, 2004, WHO INT HISTOLOGICAL-
dc.description.citedreferenceKalir T, 2002, CANCER, V94, P1078, DOI 10.1002/cncr.10280-
dc.description.citedreferenceWong CYO, 2001, EUR J NUCL MED, V28, P1702-
dc.description.citedreferenceWang BY, 2000, CANCER, V88, P2774-
dc.description.citedreferenceBrown RS, 1999, J NUCL MED, V40, P556-
dc.description.citedreferenceIto T, 1998, MODERN PATHOL, V11, P437-
dc.description.citedreferenceTravis WD, 1998, HUM PATHOL, V29, P272-
dc.description.citedreferenceBaer SC, 1997, J AM ACAD DERMATOL, V37, P575-
dc.description.citedreferenceYounes M, 1997, CANCER, V80, P1046-
dc.description.citedreferenceVoldstedlund M, 1997, APMIS, V105, P537-
dc.description.citedreferenceHaber RS, 1997, THYROID, V7, P363-
dc.description.citedreferenceYounes M, 1997, CANCER EPIDEM BIOMAR, V6, P303-
dc.description.citedreferenceYounes M, 1996, CLIN CANCER RES, V2, P1151-
dc.description.citedreferenceYounes M, 1996, CANCER RES, V56, P1164-
dc.description.citedreferenceYounes M, 1995, ANTICANCER RES, V15, P2895-
dc.description.citedreferenceNAGASE Y, 1995, J UROLOGY, V153, P798-
dc.description.citedreferenceMELLANEN P, 1994, INT J CANCER, V56, P622-
dc.description.citedreferenceBROWN RS, 1993, CANCER, V72, P2979-
dc.description.citedreferenceTAKATA K, 1992, CELL TISSUE RES, V267, P407-
dc.description.citedreferencePESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911-
dc.description.citedreferencePARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035-
dc.description.citedreferenceISSELBAC.KJ, 1972, NEW ENGL J MED, V286, P929-
dc.description.tc0-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share